Skip to main content

Table 2 Comparison of PTV doses calculated from PVP, HAP and non-enhanced CTs

From: Hepatic arterial phase and portal venous phase computed tomography for dose calculation of stereotactic body radiation therapy plans in liver cancer: a dosimetric comparison study

 

Dp

Da

Dn

P(p,a,n)*

(Dn-Dp)/Dn(%)

P(p,n)#

(Dn-Da)/Dn(%)

P(a,n)#

(Da-Dp)/Dn(%)

P(p,a)#

3D-CRT

          

CI

0.84 ± 0.07

0.83 ± 0.07

0.83 ± 0.07

0.116

-1.15 ± 2.44

-

-0.49 ± 1.72

-

-0.66 ± 1.00

-

HI

0.17 ± 0.02

0.17 ± 0.02

0.17 ± 0.02

0.117

1.04 ± 4.84

-

-0.50 ± 5.77

-

1.54 ± 4.29

-

D98% (Gy)

46.83 ± 0.28

47.09 ± 0.41

47.36 ± 0.46

0.000

1.12 ± 0.78

0.000

0.56 ± 0.51

0.000

0.56 ± 0.58

0.000

D95% (Gy)

48.09 ± 0.06

48.36 ± 0.29

48.62 ± 0.40

0.000

1.10 ± 0.76

0.000

0.54 ± 0.58

0.000

0.56 ± 0.56

0.000

D50% (Gy)

53.17 ± 0.52

53.52 ± 0.57

53.83 ± 0.75

0.000

1.23 ± 0.81

0.000

0.58 ± 0.54

0.000

0.64 ± 0.56

0.000

D2% (Gy)

55.63 ± 1.14

56.09 ± 1.28

56.39 ± 1.43

0.000

1.33 ± 1.21

0.000

0.53 ± 1.09

0.000

0.81 ± 0.93

0.000

IMRT

          

CI

0.85 ± 0.04

0.82 ± 0.06

0.79 ± 0.09

0.000

-8.60 ± 9.78

0.000

-4.34 ± 6.09

0.000

-4.25 ± 5.84

0.000

HI

0.05 ± 0.01

0.06 ± 0.01

0.06 ± 0.01

0.040

4.82 ± 8.30

0.006

2.58 ± 5.74

0.070

2.24 ± 5.70

0.111

D98% (Gy)

47.60 ± 0.20

47.85 ± 0.30

48.06 ± 0.45

0.000

0.94 ± 0.68

0.000

0.43 ± 0.49

0.000

0.51 ± 0.43

0.000

D95% (Gy)

48.05 ± 0.08

48.31 ± 0.23

48.54 ± 0.35

0.000

1.01 ± 0.72

0.000

0.46 ± 0.50

0.000

0.55 ± 0.51

0.000

D50% (Gy)

49.24 ± 0.30

49.54 ± 0.43

49.80 ± 0.48

0.000

1.11 ± 0.83

0.000

0.52 ± 0.62

0.000

0.59 ± 0.53

0.000

D2% (Gy)

50.28 ± 0.45

50.61 ± 0.51

50.91 ± 0.60

0.000

1.23 ± 0.99

0.000

0.59 ± 0.74

0.000

0.64 ± 0.66

0.000

VMAT

          

CI

0.81 ± 0.08

0.79 ± 0.08

0.78 ± 0.10

0.000

-4.93 ± 6.74

0.000

-2.38 ± 4.89

0.002

-2.54 ± 2.91

0.000

HI

0.07 ± 0.02

0.08 ± 0.02

0.08 ± 0.02

0.137

1.92 ± 6.65

-

-0.51 ± 4.73

-

2.43 ± 4.11

-

D98% (Gy)

47.45 ± 0.23

47.67 ± 0.32

47.89 ± 0.47

0.000

0.90 ± 0.64

0.000

0.45 ± 0.45

0.000

0.45 ± 0.38

0.000

D95% (Gy)

48.06 ± 0.04

48.28 ± 0.21

48.51 ± 0.31

0.000

0.93 ± 0.66

0.000

0.47 ± 0.42

0.000

0.46 ± 0.44

0.000

D50% (Gy)

49.98 ± 0.41

50.27 ± 0.51

50.52 ± 0.51

0.000

1.06 ± 0.79

0.000

0.49 ± 0.51

0.000

0.58 ± 0.52

0.000

D2% (Gy)

51.19 ± 0.62

51.54 ± 0.76

51.78 ± 0.80

0.000

1.13 ± 0.87

0.000

0.46 ± 0.53

0.000

0.68 ± 0.59

0.000

  1. Abbrevations: PVP, portal venous phase; HAP, hepatic arterial phase. Dp, Da and Dn were the dose calculated from portal venous phase, hepatic arterial phase and non-enhanced phase CTs respectively. 98%, 95%, 50% and 2%, were the minimum absorbed dose that covers 98%, 95%, 50% and 2% of the volume of the PTV respectively. CI, the conformity index; HI, the heterogeneity index. *, Friedman test; #, Wilcoxon signed ranks test.